{
    "pmcid": "10148623",
    "qa_pairs": {
        "What advantage do nanobodies have over conventional antibodies according to the summary?": [
            "Ability to access cryptic epitopes due to their small size and stability",
            "Higher sequence identity with \u03b2-coronaviruses",
            "Greater variability in the receptor-binding domain",
            "Inability to modulate protein function"
        ],
        "What challenge is associated with targeting the SARS-CoV-2 spike protein for vaccine development?": [
            "Significant sequence variability in the receptor-binding domain",
            "High sequence identity among \u03b2-coronaviruses",
            "Inaccessibility to antibodies due to its internal location",
            "Lack of surface exposure making it difficult to target"
        ],
        "What is the primary role of the SARS-CoV-2 spike protein as described in the summary?": [
            "Facilitating viral entry into host cells",
            "Disrupting host cell calcium signaling",
            "Modulating ER-mitochondria contact sites",
            "Acting as a therapeutic target for nanobodies"
        ],
        "What potential therapeutic application of nanobodies is highlighted in the summary?": [
            "Reversing phenotypic changes induced by the E protein",
            "Enhancing sequence variability in the spike protein",
            "Increasing immune escape capabilities",
            "Reducing cross-reactivity with other variants"
        ],
        "Which structural proteins are suggested as alternative therapeutic targets besides the spike protein?": [
            "Envelope (E) and membrane (M) proteins",
            "Nucleocapsid (N) and spike (S) proteins",
            "Polymerase (P) and nucleocapsid (N) proteins",
            "Envelope (E) and spike (S) proteins"
        ]
    }
}